DBD vs EW · P/E 28, rev $3.75B vs P/E 47, rev $1.39B
Diebold Nixdorf, Incorporated (DBD) versus Edwards Lifesciences Corp (EW) — a side-by-side from cached financials, not a winner call.
Diebold Nixdorf, Incorporated (DBD) is a software - application company listed on US.
Edwards Lifesciences Corp (EW) is a medical devices company listed on NYSE.
Latest reported DBD revenue for 2024-12-31 was $3.75B. Net income was -$14.5M. Revenue was up 130.3% from 2023-12-31 to 2024-12-31. DBD currently screens at market cap $2.82B and trailing P/E 28.1.
Latest reported EW revenue for 2024-12-31 was $1.39B. Net income was $385.6M. Revenue was up 2.3% from 2024-09-30 to 2024-12-31. EW currently screens at market cap $49.91B and trailing P/E 46.9.
DBD currently screens at market cap $2.82B and trailing P/E 28.1. EW currently screens at market cap $49.91B and trailing P/E 46.9.
Not investment advice. Open the DBD and EW stock pages for the full models.
Not investment advice.